There are times you can find a stock with such “insane volatility” that collecting premium is like shooting fish in a barrel.
We found another one.
Bristol-Myers Squibb (NYSE: BMY).
Bristol-Myers tendered a cool $74 billion to acquire Celgene (NASDAQ: CELG) on Jan. 3. BMY sold off sharply but has since recovered nearly all the loss.
But the volatility remains elevated probably because the merger has yet to be approved. There’s plenty of talk of an activist hedge fund holding back support.
Watch my latest Trade Scan video to find out you can trade this “insane volatility” merger play to generate a big premium for relatively little risk.
About The Author
Meet Jon Lewis, With over 20 years of real experience, teaching AND trading, Jon will help you learn to use options profitably and safely in portfolios of any size.
His advantage, and now yours, is using simple, often overlooked spread options strategies which generate consistent income without significant risk.